Human Signal Transduction ELISA Kits
Human ASPN (Asporin) ELISA Kit (HUES01712)
- SKU:
- HUES01712
- Product Type:
- ELISA Kit
- Size:
- 96 Assays
- Uniprot:
- Q9BXN1
- Sensitivity:
- 0.19ng/mL
- Range:
- 0.31-20ng/mL
- ELISA Type:
- Sandwich
- Synonyms:
- OS3, PLAP-1, PLAP1, SLRR1C
- Reactivity:
- Human
- Sample Type:
- Serum, plasma and other biological fluids
- Research Area:
- Signal Transduction
Description
Assay type: | Sandwich |
Format: | 96T |
Assay time: | 4.5h |
Reactivity: | Human |
Detection Method: | Colormetric |
Detection Range: | 0.31-20 ng/mL |
Sensitivity: | 0.19 ng/mL |
Sample Volume Required Per Well: | 100µL |
Sample Type: | Serum, plasma and other biological fluids |
Specificity: | This kit recognizes Human ASPN in samples. No significant cross-reactivity or interference between Human ASPN and analogues was observed. |
This ELISA kit uses Sandwich-ELISA as the method. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human ASPN. Standards or samples are added to the appropriate micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human ASPN and Avidin-Horseradish Peroxidase (HRP) conjugate are added to each micro plate well successively and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human ASPN, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by adding Stop Solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human ASPN. The concentration of Human ASPN in samples can be calculated by comparing the OD of the samples to the standard curve.
UniProt Protein Function: | ASPN: Negatively regulates periodontal ligament (PDL) differentiation and mineralization to ensure that the PDL is not ossified and to maintain homeostasis of the tooth-supporting system. Inhibits BMP2-induced cytodifferentiation of PDL cells by preventing its binding to BMPR1B/BMP type-1B receptor, resulting in inhibition of BMP-dependent activation of SMAD proteins. Critical regulator of TGF-beta in articular cartilage and plays an essential role in cartilage homeostasis and osteoarthritis (OA) pathogenesis. Negatively regulates chondrogenesis in the articular cartilage by blocking the TGF- beta/receptor interaction on the cell surface and inhibiting the canonical TGF-beta/Smad signal. Binds calcium and plays a role in osteoblast-driven collagen biomineralization activity. Genetic variations in ASPN are associated with susceptibility to osteoarthritis type 3 (OS3); also known as osteoarthritis of knee/hip. Osteoarthritis is a degenerative disease of the joints characterized by degradation of the hyaline articular cartilage and remodeling of the subchondral bone with sclerosis. Clinical symptoms include pain and joint stiffness often leading to significant disability and joint replacement. Susceptibility to osteoarthritis is conferred by a triplet repeat expansion polymorphism. ASPN allele having 14 aspartic acid repeats in the N-terminal region of the protein (D14), is overrepresented relative to the common allele having 13 aspartic acid repeats (D13). The frequency of the D14 allele increases with disease severity. The D14 allele is also overrepresented in individuals with hip osteoarthritis. Defects in ASPN are a cause of susceptibility to intervertebral disk disease (IDD). A common musculo- skeletal disorder caused by degeneration of intervertebral disks of the lumbar spine. It results in low-back pain and unilateral leg pain. Susceptibility to intervertebral disk disease, particularly lumbar disk degeneration, is conferred by a triplet repeat expansion polymorphism. ASPN allele having 14 aspartic acid repeats in the N-terminal region of the protein (D14), is associated with the disorder in some populations (PubMed:18304494). Belongs to the small leucine-rich proteoglycan (SLRP) family. SLRP class I subfamily. |
UniProt Protein Details: | Protein type:Extracellular matrix; Secreted; Secreted, signal peptide Chromosomal Location of Human Ortholog: 9q22. 31 Cellular Component: cytoplasm; extracellular matrix; proteinaceous extracellular matrix Molecular Function:calcium ion binding; protein kinase inhibitor activity Biological Process: bone mineralization; cytokine and chemokine mediated signaling pathway; negative regulation of JAK-STAT cascade; negative regulation of protein kinase activity; negative regulation of transforming growth factor beta receptor signaling pathway Disease: Intervertebral Disc Disease; Osteoarthritis Susceptibility 3 |
NCBI Summary: | This gene encodes a cartilage extracellular protein that is member of the small leucine-rich proteoglycan family. The encoded protein may regulate chondrogenesis by inhibiting transforming growth factor-beta 1-induced gene expression in cartilage. This protein also binds collagen and calcium and may induce collagen mineralization. Polymorphisms in the aspartic acid repeat region of this gene are associated with a susceptibility to osteoarthritis, and also with intervertebral disc disease. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, Jul 2014] |
UniProt Code: | Q9BXN1 |
NCBI GenInfo Identifier: | 209572589 |
NCBI Gene ID: | 54829 |
NCBI Accession: | Q9BXN1. 2 |
UniProt Secondary Accession: | Q9BXN1,Q5TBF3, Q96K79, Q96LD0, Q9NXP3, |
UniProt Related Accession: | Q9BXN1 |
Molecular Weight: | 43kDa |
NCBI Full Name: | Asporin |
NCBI Synonym Full Names: | asporin |
NCBI Official Symbol: | ASPN |
NCBI Official Synonym Symbols: | OS3; PLAP1; PLAP-1; SLRR1C |
NCBI Protein Information: | asporin |
UniProt Protein Name: | Asporin |
UniProt Synonym Protein Names: | Periodontal ligament-associated protein 1; PLAP-1 |
Protein Family: | Asporin |
UniProt Gene Name: | ASPN |
As the OD values of the standard curve may vary according to the conditions of the actual assay performance (e. g. operator, pipetting technique, washing technique or temperature effects), the operator should establish a standard curve for each test. Typical standard curve and data is provided below for reference only.
Concentration (ng/mL) | O.D | Average | Corrected |
20 | 2.308 2.324 | 2.316 | 2.238 |
10 | 1.539 1.583 | 1.561 | 1.483 |
5 | 0.866 0.856 | 0.861 | 0.783 |
2.5 | 0.388 0.408 | 0.398 | 0.32 |
1.25 | 0.26 0.232 | 0.246 | 0.168 |
0.63 | 0.175 0.163 | 0.169 | 0.091 |
0.31 | 0.116 0.134 | 0.125 | 0.047 |
0 | 0.076 0.08 | 0.078 | -- |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, mid range and high level Human ASPN were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, mid range and high level Human ASPN were tested on 3 different plates, 20 replicates in each plate.
Intra-assay Precision | Inter-assay Precision | |||||
Sample | 1 | 2 | 3 | 1 | 2 | 3 |
n | 20 | 20 | 20 | 20 | 20 | 20 |
Mean (ng/mL) | 1.05 | 2.51 | 9.49 | 1.12 | 2.65 | 8.77 |
Standard deviation | 0.07 | 0.10 | 0.49 | 0.08 | 0.11 | 0.40 |
C V (%) | 6.67 | 3.98 | 5.16 | 7.14 | 4.15 | 4.56 |
Recovery
The recovery of Human ASPN spiked at three different levels in samples throughout the range of the assay was evaluated in various matrices.
Sample Type | Range (%) | Average Recovery (%) |
Serum (n=5) | 93-107 | 99 |
EDTA plasma (n=5) | 91-106 | 98 |
Cell culture media (n=5) | 95-111 | 101 |
Linearity
Samples were spiked with high concentrations of Human ASPN and diluted with Reference Standard & Sample Diluent to produce samples with values within the range of the assay.
Serum (n=5) | EDTA plasma (n=5) | Cell culture media (n=5) | ||
1:2 | Range (%) | 93-109 | 93-106 | 94-106 |
Average (%) | 99 | 100 | 99 | |
1:4 | Range (%) | 94-104 | 79-93 | 85-99 |
Average (%) | 99 | 86 | 91 | |
1:8 | Range (%) | 90-106 | 80-92 | 83-94 |
Average (%) | 97 | 86 | 87 | |
1:16 | Range (%) | 88-101 | 86-100 | 89-99 |
Average (%) | 94 | 93 | 94 |
An unopened kit can be stored at 4°C for 1 month. If the kit is not used within 1 month, store the items separately according to the following conditions once the kit is received.
Item | Specifications | Storage |
Micro ELISA Plate(Dismountable) | 8 wells ×12 strips | -20°C, 6 months |
Reference Standard | 2 vials | |
Concentrated Biotinylated Detection Ab (100×) | 1 vial, 120 µL | |
Concentrated HRP Conjugate (100×) | 1 vial, 120 µL | -20°C(shading light), 6 months |
Reference Standard & Sample Diluent | 1 vial, 20 mL | 4°C, 6 months |
Biotinylated Detection Ab Diluent | 1 vial, 14 mL | |
HRP Conjugate Diluent | 1 vial, 14 mL | |
Concentrated Wash Buffer (25×) | 1 vial, 30 mL | |
Substrate Reagent | 1 vial, 10 mL | 4°C(shading light) |
Stop Solution | 1 vial, 10 mL | 4°C |
Plate Sealer | 5 pieces | |
Product Description | 1 copy | |
Certificate of Analysis | 1 copy |
- Set standard, test sample and control (zero) wells on the pre-coated plate and record theirpositions. It is recommended to measure each standard and sample in duplicate. Note: addall solutions to the bottom of the plate wells while avoiding contact with the well walls. Ensuresolutions do not foam when adding to the wells.
- Aliquot 100 µL of standard solutions into the standard wells.
- Add 100 µL of Sample / Standard dilution buffer into the control (zero) well.
- Add 100 µL of properly diluted sample (serum, plasma, tissue homogenates and otherbiological fluids) into test sample wells.
- Cover the plate with the sealer provided in the kit and incubate for 90 min at 37 °C.
- Aspirate the liquid from each well, do not wash. Immediately add 100 µL of BiotinylatedDetection Ab working solution to each well. Cover the plate with a plate seal and gently mix. Incubate for 1 hour at 37 °C.
- Aspirate or decant the solution from the plate and add 350 µL of wash buffer to each welland incubate for 1-2 minutes at room temperature. Aspirate the solution from each well andclap the plate on absorbent filter paper to dry. Repeat this process 3 times. Note: a microplatewasher can be used in this step and other wash steps.
- Add 100 µL of HRP Conjugate working solution to each well. Cover with a plate seal andincubate for 30 min at 37 °C.
- Aspirate or decant the solution from each well. Repeat the wash process for five times asconducted in step 7.
- Add 90 µL of Substrate Reagent to each well. Cover with a new plate seal and incubate forapproximately 15 min at 37 °C. Protect the plate from light. Note: the reaction time can beshortened or extended according to the actual color change, but not by more than 30min.
- Add 50 µL of Stop Solution to each well. Note: Adding the stop solution should be done inthe same order as the substrate solution.
- Determine the optical density (OD value) of each well immediately with a microplate readerset at 450 nm.